Altuvoct (efanesoctocog alfa)
OrphanAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- efanesoctocog alfa
- Company
- Swedish Orphan Biovitrum AB (publ)
- Status
- Authorised
- Therapeutic area
- Hemophilia A
- CHMP opinion
- Thu 25 Apr 2024
- EU approval
- Mon 17 Jun 2024
- Designations
- Orphan, Additional monitoring
- Application
- EMEA/H/C/005968
- ATC
- B02BD02
- Official record
- www.ema.europa.eu
Indication
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Altuvoct can be used for all age groups.
Regulatory milestones
No milestones recorded in the last year.
Follow Altuvoct
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.